These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36709750)

  • 41. Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors.
    Lyu J; Zhang Q; Chen CL; Xu Y; Ji XD; Li JK; Huang QJ; Zhao PQ
    Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1719-1725. PubMed ID: 28324112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial.
    Fidler M; Fleck BW; Stahl A; Marlow N; Chastain JE; Li J; Lepore D; Reynolds JD; Chiang MF; Fielder AR;
    Transl Vis Sci Technol; 2020 Jul; 9(8):43. PubMed ID: 32855889
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of aqueous humor levels of PlGF and VEGF in proliferative diabetic retinopathy before and after intravitreal conbercept injection.
    Zhang X; Wu J; Wu C; Bian AL; Geng S; Dai RP
    Diabetes Res Clin Pract; 2020 Apr; 162():108083. PubMed ID: 32057965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity.
    Meng Q; Cheng Y; Wu X; Zhao D; Zhao M; Liang J
    Clin Exp Optom; 2020 Jul; 103(4):495-500. PubMed ID: 31802528
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients-Retrospective Interventional Study.
    Chen L; Feng J; Shi Y; Luan F; Ma F; Wang Y; Yang W; Tao Y
    Front Med (Lausanne); 2021; 8():710079. PubMed ID: 34621759
    [No Abstract]   [Full Text] [Related]  

  • 46. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
    Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity.
    Bassiouny RM; Gaafar WM; El Nokrashy A; Abdelhameed AG; Attallah EA; Elgharieb AG; Bassiouny MR
    Eye (Lond); 2022 Nov; 36(11):2137-2143. PubMed ID: 34711941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.
    Messias K; Barroso RM; Jorge R; Messias A
    Doc Ophthalmol; 2018 Oct; 137(2):121-129. PubMed ID: 30209775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
    Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
    Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
    Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab Injection.
    Zhou M; Wang J; Wang W; Huang W; Ding X; Zhang X
    PLoS One; 2016; 11(1):e0146993. PubMed ID: 26785251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
    Tong Q; Yin H; Zhao M; Li X; Yu W
    BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
    Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
    Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma.
    Guo X; Wang Y; Yang L; Wang P; Chen K; Zhou L; Wu Y
    Int Ophthalmol; 2021 Aug; 41(8):2869-2877. PubMed ID: 33895882
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
    Sukgen EA; Koçluk Y
    Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.
    Stahl A; Krohne TU; Eter N; Oberacher-Velten I; Guthoff R; Meltendorf S; Ehrt O; Aisenbrey S; Roider J; Gerding H; Jandeck C; Smith LEH; Walz JM;
    JAMA Pediatr; 2018 Mar; 172(3):278-286. PubMed ID: 29309486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema.
    Zhou Q; Guo C; You A; Wang D; Wang W; Zhang X
    Mol Vis; 2019; 25():636-644. PubMed ID: 31700228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short-term effects of intravitreal anti-vascular endothelial growth factor agents on body weight and multiple systems after treatment for retinopathy of prematurity.
    Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
    Front Pediatr; 2022; 10():1077137. PubMed ID: 36760690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography.
    Al Rasheed R; Adhi MI; Alowedi SA; Albdah B; Aldebasi T; Hazzazi MA
    Int J Retina Vitreous; 2022 Aug; 8(1):53. PubMed ID: 35918740
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
    Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
    Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.